Dennyson Savariraj A, Salih A, Alam F, Elsherif M, Alqattan B, Khan A
ACS Sens. 2021; 6(6):2046-2076.
PMID: 34043907
PMC: 8294612.
DOI: 10.1021/acssensors.1c00370.
Mitsuoka Y, Soma T, Maruyama K, Nishida K
BMC Ophthalmol. 2021; 21(1):224.
PMID: 34011297
PMC: 8135165.
DOI: 10.1186/s12886-021-01981-9.
Fan W, Han H, Chen Y, Zhang X, Gao Y, Li S
Drug Deliv Transl Res. 2021; 11(4):1352-1375.
PMID: 33840082
DOI: 10.1007/s13346-021-00966-x.
Karachrysafi S, Sioga A, Komnenou A, Karamitsos A, Xioteli M, Dori I
Pharmaceuticals (Basel). 2020; 13(10).
PMID: 32977587
PMC: 7598222.
DOI: 10.3390/ph13100267.
Kalkanci A, Bilgihan K, Ozdemir H, Saglam A, Karakurt F, Erdogan M
Mycopathologia. 2017; 183(2):329-336.
PMID: 29043533
DOI: 10.1007/s11046-017-0207-8.
Successful treatment of Fusarium keratitis after photo refractive keratectomy.
Cavallini G, Ducange P, Volante V, Benatti C
Indian J Ophthalmol. 2013; 61(11):669-71.
PMID: 24178402
PMC: 3959087.
DOI: 10.4103/0301-4738.120213.
Hp-β-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment.
Pawar P, Kashyap H, Malhotra S, Sindhu R
Biomed Res Int. 2013; 2013:341218.
PMID: 23762839
PMC: 3665163.
DOI: 10.1155/2013/341218.
Clinical experience treating Paecilomyces lilacinus keratitis in four patients.
Monden Y, Sugita M, Yamakawa R, Nishimura K
Clin Ophthalmol. 2012; 6:949-53.
PMID: 22791978
PMC: 3392915.
DOI: 10.2147/OPTH.S29379.
The efficacy of voriconazole in 24 ocular Fusarium infections.
Troke P, Obenga G, Gaujoux T, Goldschmidt P, Bienvenu A, Cornet M
Infection. 2012; 41(1):15-20.
PMID: 22718362
DOI: 10.1007/s15010-012-0273-2.
Comparison of natamycin and voriconazole for the treatment of fungal keratitis.
Prajna N, Mascarenhas J, Krishnan T, Reddy P, Prajna L, Srinivasan M
Arch Ophthalmol. 2010; 128(6):672-8.
PMID: 20547942
PMC: 3774126.
DOI: 10.1001/archophthalmol.2010.102.
Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.
Al-Badriyeh D, Neoh C, Stewart K, Kong D
Clin Ophthalmol. 2010; 4:391-405.
PMID: 20463910
PMC: 2866570.
DOI: 10.2147/opth.s6374.
Prospective open-label study of the administration of two-percent voriconazole eye drops.
Al-Badriyeh D, Leung L, Roydhouse T, Fullinfaw R, Daniell M, Davies G
Antimicrob Agents Chemother. 2009; 53(7):3153-5.
PMID: 19433565
PMC: 2704690.
DOI: 10.1128/AAC.01700-08.
Aqueous humor concentration of voriconazole after topical administration in rabbits.
Vorwerk C, Streit F, Binder L, Tuchen S, Knop C, Behrens-Baumann W
Graefes Arch Clin Exp Ophthalmol. 2008; 246(8):1179-83.
PMID: 18491124
DOI: 10.1007/s00417-008-0849-9.
[Fusarium keratitis].
Augsten R, Dawczynski J, Pfister W, Codina C, Konigsdorffer E
Ophthalmologe. 2008; 105(11):1043-5.
PMID: 18431581
DOI: 10.1007/s00347-008-1727-x.
Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.
Yavas G, Ozturk F, Kusbeci T, Cetinkaya Z, Ermis S, Kiraz N
Graefes Arch Clin Exp Ophthalmol. 2007; 246(2):275-9.
PMID: 17912543
DOI: 10.1007/s00417-007-0687-1.
The use of voriconazole in the treatment of Aspergillus fumigatus keratitis.
Stewart R, Quah S, Neal T, Kaye S
Br J Ophthalmol. 2007; 91(8):1094-6.
PMID: 17638830
PMC: 1954810.
DOI: 10.1136/bjo.2006.111989.
Voriconazole : a review of its use in the management of invasive fungal infections.
Scott L, Simpson D
Drugs. 2007; 67(2):269-98.
PMID: 17284090
DOI: 10.2165/00003495-200767020-00009.
Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.
Thiel M, Zinkernagel A, Burhenne J, Kaufmann C, Haefeli W
Antimicrob Agents Chemother. 2006; 51(1):239-44.
PMID: 17060517
PMC: 1797668.
DOI: 10.1128/AAC.00762-06.
Topical voriconazole as a novel treatment for fungal keratitis.
Sponsel W, Chen N, Dang D, Paris G, Graybill J, Najvar L
Antimicrob Agents Chemother. 2005; 50(1):262-8.
PMID: 16377696
PMC: 1346788.
DOI: 10.1128/AAC.50.1.262-268.2006.